
1. Sci Rep. 2021 Oct 25;11(1):20964. doi: 10.1038/s41598-021-00243-4.

Treatment for COVID-19-a cohort study from Northern Italy.

Guglielmetti L(1)(2)(3), Aschieri D(4), Kontsevaya I(5)(6)(7), Calabrese F(8),
Donisi A(9), Faggi A(8), Ferrante P(8)(10), Fronti E(8), Gerna L(8), Leoni MC(8),
Paolillo F(8), Ratti G(8), Ruggieri A(8), Sacchini D(8), Scotti M(8), Valdatta
C(8), Stabile M(11), Taliani G(8)(12)(13), Codeluppi M(8).

Author information: 
(1)Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies
Infectieuses, Cimi-Paris, équipe 13, Paris, France. lorenzo.guglielmetti@aphp.fr.
(2)APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital
Pitié-Salpêtrière, Centre National de Référence Des Mycobactéries Et de La
Résistance Des Mycobactéries Aux Antituberculeux, Paris, France.
lorenzo.guglielmetti@aphp.fr.
(3)Infectious Diseases Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy.
lorenzo.guglielmetti@aphp.fr.
(4)Cardiology Unit, Castel San Giovanni Hospital, Piacenza, Italy.
(5)Research Center Borstel, Borstel, Germany.
(6)German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems, Borstel,
Germany.
(7)International Health/Infectious Diseases, University of Lübeck, Lübeck,
Germany.
(8)Infectious Diseases Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy.
(9)Migration Health Unit, Primary Health Care Department, Guglielmo da Saliceto
Hospital, Piacenza, Italy.
(10)Institute for Cross-Disciplinary Physics and Complex Systems IFISC
(UIB-CSIC), Campus Universitat Illes Balears, 07122, Palma de Mallorca, Spain.
(11)Plastic Surgery Unit, Castel San Giovanni Hospital, Piacenza, Italy.
(12)Infectious and Tropical Disease Unit, Department of Translational and
Precision Medicine, Sapienza University of Rome, Rome, Italy.
(13)Anti-COVID Task Force of the Italian Civil Protection, Rome, Italy.

Multicentre, retrospective cohort study with multivariable Cox
proportional-hazards modelling and survival-time inverse-probability-weighting,
evaluating the impact of different treatments on survival of proven COVID-19
patients admitted to two Hospitals in the province of Piacenza, Italy. Use of
tocilizumab and of high doses of low molecular weight heparin, but not of
antivirals (either alone or in combination), azithromycin, and any
corticosteroid, was independently associated with lower mortality. Our results
support further clinical evaluation of high doses of low molecular weight heparin
and tocilizumab as COVID-19 therapeutics.

© 2021. The Author(s).

DOI: 10.1038/s41598-021-00243-4 
PMCID: PMC8545945
PMID: 34697322  [Indexed for MEDLINE]

